Sonoma Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SNOA)

$4.39 +0.10 (+2.33 %)
(As of 02/23/2018 03:48 AM ET)
Previous Close$4.29
Today's Range$4.31 - $4.46
52-Week Range$4.16 - $8.25
Volume16,500 shs
Average Volume23,842 shs
Market Capitalization$19.33 million
P/E Ratio-1.52
Dividend YieldN/A
Beta0.97

About Sonoma Pharmaceuticals (NASDAQ:SNOA)

Sonoma Pharmaceuticals logoSonoma Pharmaceuticals, Inc., formerly Oculus Innovative Sciences, Inc., is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company's product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid. Microcyn is a small-molecule oxychlorine compound with antimicrobial and anti-inflammatory properties that, in clinical settings, reduces itch and pain associated with dermal irritations and wounds, such as sores, injuries and ulcers of dermal tissue. Lipogrid Technology contains selected lipids and a lipid precursor designed to penetrate the bilayers of the skin by blending with the natural lipid building blocks. Its products serve over five million patients across the globe by reducing infections, itch, pain, scarring and inflammatory responses. Its products are sold throughout the United States and internationally.

Receive SNOA News and Ratings via Email

Sign-up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:SNOA
CUSIPN/A
Phone+1-707-2830550

Debt

Debt-to-Equity Ratio0.01%
Current Ratio4.62%
Quick Ratio3.83%

Price-To-Earnings

Trailing P/E Ratio-1.51903114186851
Forward P/E Ratio-1.62
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.82 million
Price / Sales1.62
Cash FlowN/A
Price / CashN/A
Book Value$3.01 per share
Price / Book1.46

Profitability

Trailing EPS($2.89)
Net Income$9.27 million
Net Margins-70.46%
Return on Equity-70.95%
Return on Assets-57.86%

Miscellaneous

Employees243
Outstanding Shares4,730,000

Sonoma Pharmaceuticals (NASDAQ:SNOA) Frequently Asked Questions

What is Sonoma Pharmaceuticals' stock symbol?

Sonoma Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNOA."

How were Sonoma Pharmaceuticals' earnings last quarter?

Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.82) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.73) by $0.09. The company earned $3.84 million during the quarter. Sonoma Pharmaceuticals had a negative net margin of 70.46% and a negative return on equity of 70.95%. View Sonoma Pharmaceuticals' Earnings History.

Where is Sonoma Pharmaceuticals' stock going? Where will Sonoma Pharmaceuticals' stock price be in 2018?

2 Wall Street analysts have issued 12 month target prices for Sonoma Pharmaceuticals' shares. Their predictions range from $7.00 to $10.00. On average, they expect Sonoma Pharmaceuticals' share price to reach $8.50 in the next year. View Analyst Ratings for Sonoma Pharmaceuticals.

What are Wall Street analysts saying about Sonoma Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sonoma Pharmaceuticals stock:

  • 1. Maxim Group analysts commented, "Sonoma reported strong sequential growth (F3Q18) with gross revenues of $4.8M driven by US and Latin America, up 46% versus the same period a year ago. US Dermatology was $2.2M up 78% versus last year. New products were a key driver of growth for the company. Net revenues were $2.9M, also showing strong growth at the prescribers level. The impact of 30 sales reps and five senior managers is manifesting as top line revenues. US revenues now represent more than 2/3 of all revenues with solid margins. The company closed the quarter with $8.6M in cash on the balance sheet." (2/8/2018)
  • 2. According to Zacks Investment Research, "Sonoma Pharmaceuticals operates as a pharmaceutical company. It develops and markets solutions for the treatment of dermatological conditions, animal health and advanced tissue care. The company operates primarily in United States, Latin America and Europe. Sonoma Pharmaceuticals formerly known as Oculus Innovative Sciences and is headquatered in Petaluma, California. " (1/19/2018)

Who are some of Sonoma Pharmaceuticals' key competitors?

Who are Sonoma Pharmaceuticals' key executives?

Sonoma Pharmaceuticals' management team includes the folowing people:

  • James J. Schutz, President, Chief Executive Officer, Director (Age 53)
  • Robert Allen Northey Ph.D., Executive Vice President - Research and Development (Age 59)
  • Bruce Thornton, Executive Vice President - International Operations and Sales (Age 52)
  • Marc Umscheid, Chief Strategy and Marketing Officer
  • Robert Miller, Chief Financial Officer, Chief Operating Officer, Secretary (Age 73)
  • Jerry G. McLaughlin, Lead Independent Director (Age 68)
  • Sharon A. Barbari, Independent Director (Age 62)
  • Jay E. Birnbaum Ph.D., Independent Director (Age 71)
  • Russell Harrison, Independent Director (Age 71)

Who owns Sonoma Pharmaceuticals stock?

Sonoma Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.26%), JW Asset Management LLC (0.88%) and Deutsche Bank AG (0.54%). Company insiders that own Sonoma Pharmaceuticals stock include James J Schutz, Marc Umscheid and Robert E Miller. View Institutional Ownership Trends for Sonoma Pharmaceuticals.

Who sold Sonoma Pharmaceuticals stock? Who is selling Sonoma Pharmaceuticals stock?

Sonoma Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including JW Asset Management LLC. View Insider Buying and Selling for Sonoma Pharmaceuticals.

Who bought Sonoma Pharmaceuticals stock? Who is buying Sonoma Pharmaceuticals stock?

Sonoma Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Deutsche Bank AG and Renaissance Technologies LLC. Company insiders that have bought Sonoma Pharmaceuticals stock in the last two years include James J Schutz, Marc Umscheid and Robert E Miller. View Insider Buying and Selling for Sonoma Pharmaceuticals.

How do I buy Sonoma Pharmaceuticals stock?

Shares of Sonoma Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sonoma Pharmaceuticals' stock price today?

One share of Sonoma Pharmaceuticals stock can currently be purchased for approximately $4.39.

How big of a company is Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals has a market capitalization of $19.33 million and generates $12.82 million in revenue each year. The company earns $9.27 million in net income (profit) each year or ($2.89) on an earnings per share basis. Sonoma Pharmaceuticals employs 243 workers across the globe.

How can I contact Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals' mailing address is 1129 N Mcdowell Blvd, PETALUMA, CA 94954-1110, United States. The company can be reached via phone at +1-707-2830550 or via email at [email protected]


MarketBeat Community Rating for Sonoma Pharmaceuticals (SNOA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  111 (Vote Underperform)
Total Votes:  231
MarketBeat's community ratings are surveys of what our community members think about Sonoma Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sonoma Pharmaceuticals (NASDAQ:SNOA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.503.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.50$10.50$11.00$10.00
Price Target Upside: 91.01% upside116.94% upside120.44% upside46.63% upside

Sonoma Pharmaceuticals (NASDAQ:SNOA) Consensus Price Target History

Price Target History for Sonoma Pharmaceuticals (NASDAQ:SNOA)

Sonoma Pharmaceuticals (NASDAQ:SNOA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/14/2018Maxim GroupReiterated RatingBuy -> Buy$11.00 -> $7.00LowView Rating Details
12/28/2017BenchmarkInitiated CoverageSpeculative Buy -> Speculative Buy$10.00HighView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Sonoma Pharmaceuticals (NASDAQ:SNOA) Earnings History and Estimates Chart

Earnings by Quarter for Sonoma Pharmaceuticals (NASDAQ:SNOA)

Sonoma Pharmaceuticals (NASDAQ SNOA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q2 2018($0.75)($0.67)$3.94 million$4.33 millionViewN/AView Earnings Details
8/8/2017Q1 2018($0.73)($0.82)$3.84 millionViewListenView Earnings Details
6/5/2017Q4 2017($0.67)($0.69)$4.03 millionViewListenView Earnings Details
2/9/2017Q3 2017$3.08$3.84$3.36 millionViewListenView Earnings Details
11/10/2016Q2 2017($0.46)$4.11 millionViewN/AView Earnings Details
7/28/2016Q1 2017($0.61)$3.81 millionViewN/AView Earnings Details
6/16/2016Q4($0.16)$3.53 millionViewListenView Earnings Details
2/4/2016Q216($0.07)($0.19)$3.56 million$3.80 millionViewListenView Earnings Details
11/5/2015Q2 2016($0.70)($0.55)$3.76 million$4.05 millionViewN/AView Earnings Details
7/30/2015Q116($0.10)($0.15)$3.96 million$3.70 millionViewListenView Earnings Details
6/11/2015Q215($0.25)($0.11)$3.12 million$3.98 millionViewListenView Earnings Details
2/12/2015Q115($0.18)($0.69)$3.10 million$3.22 millionViewListenView Earnings Details
11/13/2014Q2 2015($0.95)($0.85)$3.21 million$3.26 millionViewN/AView Earnings Details
8/7/2014Q1 15($0.17)($0.01)$3.13 million$3.39 millionViewN/AView Earnings Details
6/12/2014Q4 14($0.21)$0.99$3.42 million$2.91 millionViewN/AView Earnings Details
2/13/2014Q3 2014($0.80)($1.60)$3.82 million$3.29 millionViewN/AView Earnings Details
11/19/2013Q2($0.15)($0.21)$4.03 million$4.10 millionViewListenView Earnings Details
8/8/2013Q1 2014($0.26)($0.26)$3.68 million$3.37 millionViewN/AView Earnings Details
6/13/2013Q4 2013($0.55)($1.35)$3.85 million$3.34 millionViewN/AView Earnings Details
2/13/2013Q3 2013($0.08)($0.05)$3.28 million$3.50 millionViewN/AView Earnings Details
11/1/2012Q312$0.03($0.05)$5.59 million$4.50 millionViewN/AView Earnings Details
8/2/2012Q1 2013($1.75)($0.70)ViewN/AView Earnings Details
6/7/2012Q4 2012($2.45)($2.17)ViewN/AView Earnings Details
2/2/2012Q3 2012($1.75)($3.39)ViewN/AView Earnings Details
11/3/2011Q2 2012($2.10)($1.26)ViewN/AView Earnings Details
8/4/2011Q1 2012($2.10)($2.73)ViewN/AView Earnings Details
6/2/2011Q4 2011($2.45)($2.13)ViewN/AView Earnings Details
2/3/2011Q3 2011($2.45)($2.94)ViewN/AView Earnings Details
11/4/2010Q2 2011($2.20)ViewN/AView Earnings Details
8/5/2010Q1 2011($3.18)ViewN/AView Earnings Details
6/3/2010Q4 2010($1.99)ViewN/AView Earnings Details
2/4/2010Q3 2010($1.75)ViewN/AView Earnings Details
11/5/2009Q2 2010($3.25)ViewN/AView Earnings Details
8/6/2009Q1 2010($4.23)ViewN/AView Earnings Details
6/11/2009Q4 2009($4.55)ViewN/AView Earnings Details
2/12/2009Q3 2009($7.28)ViewN/AView Earnings Details
11/6/2008Q2 2009($14.35)($15.19)ViewN/AView Earnings Details
8/5/2008Q1 2009($12.95)($11.41)ViewN/AView Earnings Details
6/11/2008Q4 2008($15.75)($11.79)ViewN/AView Earnings Details
2/7/2008Q3 2008($14.00)($14.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Sonoma Pharmaceuticals (NASDAQ:SNOA) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.71 EPS
Next Year EPS Consensus Estimate: $-2.3 EPS

Dividends

Dividend History for Sonoma Pharmaceuticals (NASDAQ:SNOA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Sonoma Pharmaceuticals (NASDAQ SNOA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 12.56%
Insider Trades by Quarter for Sonoma Pharmaceuticals (NASDAQ:SNOA)
Institutional Ownership by Quarter for Sonoma Pharmaceuticals (NASDAQ:SNOA)

Sonoma Pharmaceuticals (NASDAQ SNOA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/29/2017James J SchutzCEOBuy400$5.03$2,012.0015,829View SEC Filing  
11/29/2017Robert E MillerCFOBuy1,790$5.02$8,985.8020,088View SEC Filing  
11/24/2017James J SchutzCEOBuy254$5.05$1,282.7015,429View SEC Filing  
11/21/2017Robert E MillerCFOBuy2,000$5.03$10,060.0020,088View SEC Filing  
8/10/2017James J SchutzCEOBuy929$5.46$5,072.3415,175View SEC Filing  
8/10/2017Marc UmscheidInsiderBuy600$5.31$3,186.003,392View SEC Filing  
8/10/2017Robert E MillerCFOBuy2,264$5.30$11,999.2020,088View SEC Filing  
3/9/2017Robert E MillerCFOBuy750$7.02$5,265.0015,964View SEC Filing  
3/8/2017Robert E MillerCFOBuy1,000$6.93$6,930.0015,964View SEC Filing  
3/6/2017Marc UmscheidInsiderBuy750$6.82$5,115.00750View SEC Filing  
3/3/2017James J SchutzCEOBuy800$6.78$5,424.0011,736View SEC Filing  
12/8/2016James J SchutzCEOBuy1,000$4.88$4,880.0011,040View SEC Filing  
12/8/2016Robert E MillerCFOBuy5,000$4.86$24,300.0015,964View SEC Filing  
8/15/2016James J SchutzCEOBuy1,328$3.66$4,860.486,505View SEC Filing  
2/25/2016James J SchutzCEOBuy5,000$1.00$5,000.0025,885View SEC Filing  
11/17/2014James J SchutzCEOBuy6,285$1.78$11,187.30View SEC Filing  
8/16/2013James SchutzCEOBuy5,100$2.35$11,985.0014,600View SEC Filing  
12/10/2012Hojabr AlimiCEOBuy5,500$0.64$3,520.00View SEC Filing  
12/7/2012Hojabr AlimiCEOBuy5,300$0.65$3,445.00View SEC Filing  
11/9/2012James J SchutzCOOBuy13,000$0.80$10,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sonoma Pharmaceuticals (NASDAQ SNOA) News Headlines

Source:
DateHeadline
Sonoma Pharmaceuticals (SNOA) PT Lowered to $7 at Maxim Group - StreetInsider.comSonoma Pharmaceuticals (SNOA) PT Lowered to $7 at Maxim Group - StreetInsider.com
www.streetinsider.com - February 14 at 3:21 PM
Maxim Group Analysts Give Sonoma Pharmaceuticals (SNOA) a $7.00 Price TargetMaxim Group Analysts Give Sonoma Pharmaceuticals (SNOA) a $7.00 Price Target
www.americanbankingnews.com - February 14 at 1:38 PM
Sonoma Pharmaceuticals (SNOA) PT Set at $11.00 by Maxim GroupSonoma Pharmaceuticals (SNOA) PT Set at $11.00 by Maxim Group
www.americanbankingnews.com - February 11 at 12:30 PM
Sonoma Pharmaceuticals (SNOA) CEO James Schutz on Q3 2018 Results - Earnings Call Transcript - Seeking AlphaSonoma Pharmaceuticals' (SNOA) CEO James Schutz on Q3 2018 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 8 at 5:38 AM
Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year ... - GlobeNewswire (press release)Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year ... - GlobeNewswire (press release)
globenewswire.com - February 8 at 5:38 AM
Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46%Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46%
finance.yahoo.com - February 8 at 5:38 AM
Analysts Expect Sonoma Pharmaceuticals Inc (SNOA) to Announce ($0.63) EPSAnalysts Expect Sonoma Pharmaceuticals Inc (SNOA) to Announce ($0.63) EPS
www.americanbankingnews.com - February 5 at 9:46 AM
Sonoma Pharmaceuticals (SNOA) versus Syros Pharmaceuticals (SYRS) Head-To-Head ContrastSonoma Pharmaceuticals (SNOA) versus Syros Pharmaceuticals (SYRS) Head-To-Head Contrast
www.americanbankingnews.com - February 2 at 2:22 PM
Sonoma Pharmaceuticals Announces Fiscal Third Quarter 2018 Financial Results and Conference CallSonoma Pharmaceuticals Announces Fiscal Third Quarter 2018 Financial Results and Conference Call
finance.yahoo.com - February 2 at 5:43 AM
Zacks: Sonoma Pharmaceuticals Inc (SNOA) Given $11.00 Consensus Target Price by AnalystsZacks: Sonoma Pharmaceuticals Inc (SNOA) Given $11.00 Consensus Target Price by Analysts
www.americanbankingnews.com - January 31 at 5:12 PM
Head to Head Analysis: Sonoma Pharmaceuticals (SNOA) & Synlogic (SYBX)Head to Head Analysis: Sonoma Pharmaceuticals (SNOA) & Synlogic (SYBX)
www.americanbankingnews.com - January 30 at 3:18 AM
Analyzing Sonoma Pharmaceuticals (SNOA) & Cesca Therapeutics (KOOL)Analyzing Sonoma Pharmaceuticals (SNOA) & Cesca Therapeutics (KOOL)
www.americanbankingnews.com - January 27 at 11:26 AM
Sonoma Pharmaceuticals Announces Fiscal Third Quarter 2018 Financial Results and Conference Call - NasdaqSonoma Pharmaceuticals Announces Fiscal Third Quarter 2018 Financial Results and Conference Call - Nasdaq
www.nasdaq.com - January 26 at 5:46 AM
Sonoma Pharmaceuticals (SNOA) Rating Increased to Buy at Zacks Investment ResearchSonoma Pharmaceuticals (SNOA) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 19 at 3:20 PM
Zacks Investment Research Lowers Sonoma Pharmaceuticals (SNOA) to HoldZacks Investment Research Lowers Sonoma Pharmaceuticals (SNOA) to Hold
www.americanbankingnews.com - January 18 at 3:16 PM
 Sonoma Pharmaceuticals Inc (SNOA) Given $11.00 Average Price Target by Brokerages Sonoma Pharmaceuticals Inc (SNOA) Given $11.00 Average Price Target by Brokerages
www.americanbankingnews.com - January 12 at 3:42 AM
Critical Comparison: Sonoma Pharmaceuticals (SNOA) versus Optimer Pharmaceuticals (OPTR)Critical Comparison: Sonoma Pharmaceuticals (SNOA) versus Optimer Pharmaceuticals (OPTR)
www.americanbankingnews.com - January 11 at 9:34 AM
Sonoma Pharmaceuticals Receives Three New United Arab Emirates Regulatory Approvals: Acuicyn® for Management of Blepharitis, Microsafe® Oral Care for Mucositis and Sinudox® for Chronic SinusitisSonoma Pharmaceuticals Receives Three New United Arab Emirates Regulatory Approvals: Acuicyn® for Management of Blepharitis, Microsafe® Oral Care for Mucositis and Sinudox® for Chronic Sinusitis
finance.yahoo.com - January 9 at 10:34 AM
Sonoma Pharmaceuticals (SNOA) Cut to "Hold" at Zacks Investment ResearchSonoma Pharmaceuticals (SNOA) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 5 at 8:10 PM
Sonoma Pharmaceuticals, Inc. :SNOA-US: Earnings Analysis: Q2, 2018 By the Numbers : January 1, 2018Sonoma Pharmaceuticals, Inc. :SNOA-US: Earnings Analysis: Q2, 2018 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 10:29 AM
Financial Contrast: Sonoma Pharmaceuticals (SNOA) versus BioMarin Pharmaceutical (BMRN)Financial Contrast: Sonoma Pharmaceuticals (SNOA) versus BioMarin Pharmaceutical (BMRN)
www.americanbankingnews.com - December 29 at 8:16 AM
Benzingas Top Upgrades, Downgrades For December 28, 2017 - BenzingaBenzinga's Top Upgrades, Downgrades For December 28, 2017 - Benzinga
www.benzinga.com - December 28 at 1:06 PM
Sonoma Pharmaceuticals (SNOA) Receives New Coverage from Analysts at BenchmarkSonoma Pharmaceuticals (SNOA) Receives New Coverage from Analysts at Benchmark
www.americanbankingnews.com - December 28 at 8:18 AM
 Sonoma Pharmaceuticals, Inc. (SNOA) Given $11.00 Average Target Price by Brokerages Sonoma Pharmaceuticals, Inc. (SNOA) Given $11.00 Average Target Price by Brokerages
www.americanbankingnews.com - December 22 at 9:20 PM
Sonoma Pharmaceuticals Announces Second FDA Approval to Add Antimicrobial Language to Alevicyn™ Gel Products for Management of Atopic DermatitisSonoma Pharmaceuticals Announces Second FDA Approval to Add Antimicrobial Language to Alevicyn™ Gel Products for Management of Atopic Dermatitis
finance.yahoo.com - December 13 at 11:05 AM
Comparing 3SBio (SSRX) & Sonoma Pharmaceuticals (SNOA)Comparing 3SBio (SSRX) & Sonoma Pharmaceuticals (SNOA)
www.americanbankingnews.com - December 10 at 11:34 PM
Does Sonoma Pharmaceuticals Inc’s (SNOA) Recent Track Record Look Strong?Does Sonoma Pharmaceuticals Inc’s (SNOA) Recent Track Record Look Strong?
finance.yahoo.com - November 30 at 11:21 AM
Sonoma Pharmaceuticals, Inc. (SNOA) CFO Robert E. Miller Buys 2,000 SharesSonoma Pharmaceuticals, Inc. (SNOA) CFO Robert E. Miller Buys 2,000 Shares
www.americanbankingnews.com - November 24 at 4:48 PM
Sonoma Pharmaceuticals, Inc. (SNOA) Given a $11.00 Price Target at Maxim GroupSonoma Pharmaceuticals, Inc. (SNOA) Given a $11.00 Price Target at Maxim Group
www.americanbankingnews.com - November 17 at 3:54 PM
Sonoma Pharmaceuticals (SNOA) Expanded Indication for Alevicyn Approved by FDASonoma Pharmaceuticals (SNOA) Expanded Indication for Alevicyn Approved by FDA
www.streetinsider.com - November 17 at 1:55 PM
Sonoma Pharmaceuticals (SNOA) Expanded Indication for Alevicyn Approved by FDA - StreetInsider.comSonoma Pharmaceuticals (SNOA) Expanded Indication for Alevicyn Approved by FDA - StreetInsider.com
www.streetinsider.com - November 16 at 8:37 AM
Sonoma Pharmaceuticals Announces FDA Approval of Expanded Indication for Alevicyn™ to Add Antimicrobial LanguageSonoma Pharmaceuticals Announces FDA Approval of Expanded Indication for Alevicyn™ to Add Antimicrobial Language
finance.yahoo.com - November 16 at 8:37 AM
What You Must Know About Sonoma Pharmaceuticals Inc’s (SNOA) Financial StrengthWhat You Must Know About Sonoma Pharmaceuticals Inc’s (SNOA) Financial Strength
finance.yahoo.com - November 15 at 10:05 AM
Sonoma Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call SlidesSonoma Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call Slides
seekingalpha.com - November 12 at 2:51 AM
Sonoma Pharmaceuticals (SNOA) CEO Jim Schutz on Q2 2018 Results - Earnings Call Transcript - Seeking AlphaSonoma Pharmaceuticals' (SNOA) CEO Jim Schutz on Q2 2018 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 11 at 1:51 PM
Sonoma Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue ... - GlobeNewswire (press release)Sonoma Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue ... - GlobeNewswire (press release)
globenewswire.com - November 10 at 11:26 AM
Sonoma Pharmaceuticals (SNOA) PT Raised to $11 at Maxim Group - StreetInsider.comSonoma Pharmaceuticals (SNOA) PT Raised to $11 at Maxim Group - StreetInsider.com
www.streetinsider.com - November 10 at 11:26 AM
Sonoma Pharmaceuticals (SNOA) "Buy" Rating Reaffirmed at Maxim GroupSonoma Pharmaceuticals' (SNOA) "Buy" Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - November 10 at 11:24 AM
Sonoma Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue Growth and Total Revenue of $4.3 MillionSonoma Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue Growth and Total Revenue of $4.3 Million
finance.yahoo.com - November 9 at 6:50 PM
Sonoma Pharmaceuticals, Inc. to Host Earnings CallSonoma Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 1:45 PM
Sonoma Pharmaceuticals Receives Brazilian Approvals to Market Multiple Hypochlorous Acid-Based Dermatology ProductsSonoma Pharmaceuticals Receives Brazilian Approvals to Market Multiple Hypochlorous Acid-Based Dermatology Products
finance.yahoo.com - October 31 at 9:47 AM
Sonoma Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results and Conference Call - GlobeNewswire (press release)Sonoma Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results and Conference Call - GlobeNewswire (press release)
globenewswire.com - October 28 at 6:24 AM
Sonoma Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results and Conference CallSonoma Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results and Conference Call
finance.yahoo.com - October 28 at 6:24 AM
ETFs with exposure to Sonoma Pharmaceuticals, Inc. : October 25, 2017ETFs with exposure to Sonoma Pharmaceuticals, Inc. : October 25, 2017
finance.yahoo.com - October 25 at 10:53 AM
Sonoma Pharmaceuticals (SNOA) and VIVUS (VVUS) Head-To-Head ContrastSonoma Pharmaceuticals (SNOA) and VIVUS (VVUS) Head-To-Head Contrast
www.americanbankingnews.com - October 18 at 2:24 PM
Stonegate Capital Partners Updates Coverage on Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA)Stonegate Capital Partners Updates Coverage on Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA)
finance.yahoo.com - October 18 at 8:46 AM
Stonegate Capital Partners Updates Coverage on Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA)Stonegate Capital Partners Updates Coverage on Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA)
finance.yahoo.com - October 18 at 8:46 AM
Sonoma Pharmaceuticals Announces U.S. Commercialization of Loyon® for Relief of Scaling, Burning and Itching Associated with Various Dermatoses Including Seborrhea and Seborrheic DermatitisSonoma Pharmaceuticals Announces U.S. Commercialization of Loyon® for Relief of Scaling, Burning and Itching Associated with Various Dermatoses Including Seborrhea and Seborrheic Dermatitis
finance.yahoo.com - October 3 at 12:38 PM
Critical Review: Sonoma Pharmaceuticals (SNOA) vs. Its PeersCritical Review: Sonoma Pharmaceuticals (SNOA) vs. Its Peers
www.americanbankingnews.com - September 27 at 6:22 AM
Head to Head Contrast: Sonoma Pharmaceuticals (SNOA) and Its RivalsHead to Head Contrast: Sonoma Pharmaceuticals (SNOA) and Its Rivals
www.americanbankingnews.com - September 22 at 2:16 PM

SEC Filings

Sonoma Pharmaceuticals (NASDAQ:SNOA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sonoma Pharmaceuticals (NASDAQ:SNOA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sonoma Pharmaceuticals (NASDAQ SNOA) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.